Geron Corporation
NASDAQ:GERNBiotechnology
Healthcare
$0.91 +4.07%
+$0.05 today
- Market cap
- $588.19M
- Beta
- 0.60
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.10
52W Low $1.04High $2.01
Volume 19.64M
Average 16.28M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$111.04M
FY 2025 · Annual
Investing Cash Flow
$107.25M
FY 2025 · Annual
Financing Cash Flow
$2.27M
FY 2025 · Annual
-99.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Depreciation & Amortization | 783K | 868K | 1.03M | 1.22M | 1.2M |
| Deferred Income Tax | 191K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.08M | 8M | 19.35M | 31.32M | 88K |
| Change in Working Capital | 10.52M | 5.03M | 6.06M | (68.41M) | (68.54M) |
| Accounts Receivables | (1.04M) | (1.38M) | 1.49M | (36.89M) | (377K) |
| Inventory | 1.04M | 1.38M | 0 | (37.97M) | (77.92M) |
| Accounts Payables | (232K) | 3.5M | (4.03M) | 2.44M | 2.66M |
| Other Working Capital | 10.75M | 1.52M | 8.6M | 4.02M | 7.1M |
| Other Non-Cash Items | 984K | 626K | (10.06M) | (8.18M) | 41.99M |
| Operating Cash Flow | (95.56M) | (127.38M) | (167.74M) | (218.62M) | (111.04M) |
| Capital Expenditures | (207K) | (431K) | (830K) | (680K) | (49K) |
| Acquisitions (Net) | 1.59M | (1.23M) | 179.49M | 0 | 0 |
| Purchases of Investments | (177.43M) | (258.01M) | (475.59M) | (476.93M) | (304.42M) |
| Sales of Investments | 249.59M | 320.51M | 296.1M | 371.61M | 411.72M |
| Other Investing Activities | (1.59M) | 1.23M | (179.49M) | 0 | 0 |
| Investing Cash Flow | 71.95M | 62.07M | (180.32M) | (106M) | 107.25M |
| Debt Repayment | 24.9M | 0 | 29.7M | 34.57M | 0 |
| Common Stock Issued | 20.39M | 69.92M | 213.34M | 140.73M | 2.27M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.28M | 17.35M | 118.98M | 159.08M | 0 |
| Financing Cash Flow | 48.56M | 87.26M | 362.02M | 334.37M | 2.27M |
| Effect of Forex Changes | 0 | 22K | (27K) | (12K) | 87K |
| Net Change in Cash | 24.95M | 21.97M | 13.93M | 9.74M | (1.44M) |
| Free Cash Flow | (95.76M) | (127.81M) | (168.57M) | (219.3M) | (111.09M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$85.8M
+ D&A$1.2M
+ Stock-Based Comp$88.0K
+ Deferred Tax$0
- Working Capital-$68.5M
+ Other Non-Cash$42.0M
= Operating Cash Flow-$111.0M
- Capex-$49.0K
= Free Cash Flow-$111.1M
Analysis
FY2025 free cash flow is -$111.1M. FCF conversion is 129.5% of net income. Operating cash flow was -$111.0M, with capex of -$49.0K. The largest bridge item is Working Capital at -$68.5M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Oct 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 |
Does GERN generate free cash flow?
Geron Corporation (GERN) generated -$111.09M of free cash flow in fiscal 2025.
How much operating cash flow does GERN produce?
Operating cash flow was -$111.04M, before capital expenditures of $49,000.00.
Continue the stock analysis
Jump to another research area for this company.